Matching adjusted indirect comparison (MAIC) of [177Lu]Lu-DOTA-TATE (177Lu-DOTATATE) vs. CAPTEM as first-line (1L) treatment for advanced grade 3 (G3) gastroenteropancreatic neuroendocrine tumours (GEP-NETs)

#4504

Introduction: The NETTER-2 trial showed a significant progression-free survival (PFS) benefit with 1L 177Lu-DOTATATE vs. high dose octreotide for patients with advanced G2/G3 GEP-NETs. No published evidence exists comparing 177Lu-DOTATATE with other recommended 1L treatments for patients with G3 GEP-NETs, such as capecitabine + temozolomide (CAPTEM), hence indirect comparisons need to be conducted.

Aim(s): To determine the relative efficacy of 177Lu-DOTATATE vs. CAPTEM as 1L treatment for patients with advanced G3 GEP-NETs using MAIC.

Materials and methods: In the absence of randomised trials, an unanchored MAIC of PFS in patients with advanced G3 GEP-NETs treated with 1L 177Lu-DOTATATE vs. CAPTEM was conducted using individual patient data from NETTER-2 and aggregate data from a retrospective study (Apostolidis 2021). The study was selected considering the eligibility criteria for the MAIC including adequate sample size, availability of baseline characteristics, and Kaplan-Meier curve for PFS. Multiple scenarios with different combinations of covariates used in the MAIC weighting were considered with the final model (age, sex, and Ki-67 index) selected to maintain adequate effective sample size (ESS).

Conference:

Presenting Author: Deshayes E

Authors: Deshayes E, Capdevila J, Gerard L, Navalkissoor S, Srirajaskanthan R,

Keywords: gastroenteropancreatic neuroendocrine tumour, [177lu]lu-dotatate, capecitabine, temozolomide, matching adjusted indirect comparison,